Related Experiment Video
Updated: Sep 15, 2025
08:35
Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
Published on: May 26, 2022
3.5K
New Drugs for Resistant Hypertension: Pending Issue?
Francesco Fici1, Nicolas Roberto Robles2, Istemihan Tengiz3
1Department of Cardiovascular Risk, Salamanca University, Salamanca, Spain;Milano-Bicocca University, Milan, Italy.
Summary
New antihypertensive drugs are being developed to address the persistent cardiovascular risk in patients with drug-resistant hypertension. This review examines novel drug classes targeting uncontrolled high blood pressure.
Area of Science:
- Pharmacology
- Cardiovascular Medicine
- Drug Discovery
Background:
- Current antihypertensive drugs reduce cardiovascular risk but do not eliminate it.
- Elevated cardiovascular risk persists in treated hypertensive patients.
- There is a need for novel antihypertensive agents for drug-resistant hypertension.
Purpose of the Study:
- To review emerging antihypertensive drugs for treating drug-resistant hypertension.
- To highlight novel therapeutic targets and agents in hypertension management.
Main Methods:
- Literature review of recent studies on new antihypertensive drug classes.
- Focus on non-steroidal mineralocorticoid receptor antagonists, aldosterone synthase inhibitors, and others.
Main Results:
- Several novel drug classes show promise in targeting resistant hypertension.
- These include mineralocorticoid receptor antagonists, aldosterone synthase inhibitors, and brain renin-angiotensin system blockers.
Conclusions:
- Novel pharmacological approaches are crucial for managing drug-resistant hypertension.
- These new agents offer potential to further reduce cardiovascular risk in hypertensive patients.
More Related Videos
Related Concept Videos
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
511
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
511
01:25Antihypertensive Drugs: Direct Renin Inhibitors
830
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
830
01:28Hypertension IV: Drug Therapy and Lifestyle Modifications
40
Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...
40
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
928
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
928
01:22Heart Failure Drugs: Diuretics
495
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
495
01:30Heart Failure V: Medical Management
26
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
26